MX2017014002A - Moléculas de direccionamiento del sistema de secreción tipo iii . - Google Patents
Moléculas de direccionamiento del sistema de secreción tipo iii .Info
- Publication number
- MX2017014002A MX2017014002A MX2017014002A MX2017014002A MX2017014002A MX 2017014002 A MX2017014002 A MX 2017014002A MX 2017014002 A MX2017014002 A MX 2017014002A MX 2017014002 A MX2017014002 A MX 2017014002A MX 2017014002 A MX2017014002 A MX 2017014002A
- Authority
- MX
- Mexico
- Prior art keywords
- molecules
- type iii
- secretion system
- iii secretion
- specifically bind
- Prior art date
Links
- 108010069584 Type III Secretion Systems Proteins 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title 1
- 230000001580 bacterial effect Effects 0.000 abstract 3
- 101150012056 OPRL1 gene Proteins 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 102000004895 Lipoproteins Human genes 0.000 abstract 1
- 108090001030 Lipoproteins Proteins 0.000 abstract 1
- 102000018697 Membrane Proteins Human genes 0.000 abstract 1
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Esta invención esta relacionada en general a moléculas que se unen específicamente a proteínas V-tip bacterianas del sistema de secreción tipo III de bacterias Gram negativas tales como PcrV de Pseudomonas aeruginosa; más específicamente, esta invención se relaciona con moléculas que bloquean la inyección de moléculas efectoras de células objetivo; esta invención también se relaciona con moléculas de la presente invención son monoespecificas o multiespecificas y pueden unirse a su antígeno objetivo en una manera monovalente o multivalente; la inversión también está relacionada en general a moléculas se unen específicamente a proteínas de la superficie celular tales como OprI, y a métodos para usar estas moléculas en una variedad de indicadores terapéuticos de diagnóstico y/o profilácticas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562155967P | 2015-05-01 | 2015-05-01 | |
| US201562254992P | 2015-11-13 | 2015-11-13 | |
| PCT/US2016/030429 WO2016179101A2 (en) | 2015-05-01 | 2016-05-02 | Type iii secretion system targeting molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017014002A true MX2017014002A (es) | 2018-08-01 |
Family
ID=57205652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017014002A MX2017014002A (es) | 2015-05-01 | 2016-05-02 | Moléculas de direccionamiento del sistema de secreción tipo iii . |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10344078B2 (es) |
| EP (1) | EP3288974B1 (es) |
| JP (1) | JP6966330B2 (es) |
| KR (1) | KR20180020142A (es) |
| CN (1) | CN107922482A (es) |
| AU (1) | AU2016257751B2 (es) |
| BR (1) | BR112017023378A2 (es) |
| CA (1) | CA2984628C (es) |
| ES (1) | ES2846881T3 (es) |
| IL (1) | IL255329B (es) |
| MX (1) | MX2017014002A (es) |
| NZ (1) | NZ774893A (es) |
| RU (1) | RU2759949C2 (es) |
| WO (1) | WO2016179101A2 (es) |
| ZA (1) | ZA201707404B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12516129B2 (en) | 2018-12-14 | 2026-01-06 | Regeneron Pharmaceuticals, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| CN113490686B (zh) * | 2019-01-07 | 2025-02-18 | 拜科托莱夫股份有限公司 | 病原体结合蛋白 |
| JP7571347B2 (ja) | 2019-05-04 | 2024-10-23 | インヒブルクス バイオサイエンシズ インコーポレイテッド | ＣＬＥＣ１２ａ結合性ポリペプチド及びその使用 |
| US12421315B2 (en) * | 2019-05-08 | 2025-09-23 | Regeneron Pharmaceuticals, Inc. | CLL-1 targeted immunotherapies |
| CA3171363A1 (en) * | 2019-12-20 | 2021-06-24 | Kisoji Biotechnology Inc. | Polypeptides, protein complexes and method for making same |
| WO2024206569A2 (en) * | 2023-03-28 | 2024-10-03 | The Trustees Of The University Of Pennsylvania | Single domain camelid antibodies to human bcma and their use in chimeric antigen receptor (car) t cells |
| CN119044485A (zh) * | 2024-09-09 | 2024-11-29 | 重庆原伦生物科技有限公司 | 一种检测重组铜绿假单胞菌疫苗rPO抗原含量的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5094951A (en) | 1988-06-21 | 1992-03-10 | Chiron Corporation | Production of glucose oxidase in recombinant systems |
| AU3243199A (en) * | 1998-03-05 | 1999-09-20 | University Of British Columbia, The | Methods for assaying type iii secretion inhibitors |
| JP2008526205A (ja) * | 2004-12-31 | 2008-07-24 | ジェネンテック・インコーポレーテッド | Ｂｒ３に結合するポリペプチド及びその使用 |
| JP2008133206A (ja) * | 2006-11-28 | 2008-06-12 | Yokohama City Univ | 緑膿菌に対して感染防御能を誘導できる医薬組成物 |
| KR101491867B1 (ko) * | 2007-01-31 | 2015-02-10 | 피페넥스 인크. | 증가된 발현을 위한 박테리아 리더 서열 |
| SG186017A1 (en) * | 2007-11-30 | 2012-12-28 | Kalobios Pharmaceuticals Inc | Antibodies to the pcrv antigen of pseudomonas aeruginosa |
| EP2408475B1 (en) * | 2009-03-18 | 2017-11-15 | Wake Forest University Health Sciences | Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa |
| US8642039B2 (en) * | 2009-12-22 | 2014-02-04 | Kalobios Pharmaceuticals, Inc. | Method of treating a staphylococcus infection in a patient having a low-level pathogenic Pseudomonas aeruginosa infection |
| CN103270047A (zh) * | 2010-12-23 | 2013-08-28 | 因特塞尔奥地利股份公司 | Oprf/i剂及其在住院患者和其他患者中的用途 |
| EP2776061B1 (en) | 2011-11-07 | 2019-08-14 | MedImmune, LLC | Multispecific and multivalent binding proteins and uses thereof |
| BR112014011028B1 (pt) | 2011-11-07 | 2021-03-02 | Medimmune, Llc | anticorpo biespecífico, composição, e, uso da composição |
| AU2013224851B2 (en) * | 2012-03-02 | 2018-03-01 | Ablynx Nv | Pseudomonas aeruginosa PcrV binding single variable domain antibodies |
| AU2013341349A1 (en) * | 2012-11-06 | 2015-05-21 | Medimmune Limited | Combination therapies using anti-Pseudomonas Psl and PcrV binding molecules |
-
2016
- 2016-05-02 MX MX2017014002A patent/MX2017014002A/es unknown
- 2016-05-02 JP JP2017557060A patent/JP6966330B2/ja active Active
- 2016-05-02 CA CA2984628A patent/CA2984628C/en active Active
- 2016-05-02 CN CN201680038692.6A patent/CN107922482A/zh active Pending
- 2016-05-02 BR BR112017023378-9A patent/BR112017023378A2/pt not_active Application Discontinuation
- 2016-05-02 EP EP16789896.4A patent/EP3288974B1/en active Active
- 2016-05-02 KR KR1020177034743A patent/KR20180020142A/ko not_active Ceased
- 2016-05-02 WO PCT/US2016/030429 patent/WO2016179101A2/en not_active Ceased
- 2016-05-02 ES ES16789896T patent/ES2846881T3/es active Active
- 2016-05-02 NZ NZ774893A patent/NZ774893A/en not_active IP Right Cessation
- 2016-05-02 US US15/144,470 patent/US10344078B2/en active Active
- 2016-05-02 RU RU2017141738A patent/RU2759949C2/ru active
- 2016-05-02 AU AU2016257751A patent/AU2016257751B2/en not_active Ceased
-
2017
- 2017-10-30 IL IL255329A patent/IL255329B/en unknown
- 2017-10-31 ZA ZA2017/07404A patent/ZA201707404B/en unknown
-
2019
- 2019-05-22 US US16/419,677 patent/US10745466B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017141738A3 (es) | 2020-05-22 |
| BR112017023378A2 (pt) | 2018-07-24 |
| WO2016179101A2 (en) | 2016-11-10 |
| JP2018515083A (ja) | 2018-06-14 |
| US10344078B2 (en) | 2019-07-09 |
| RU2017141738A (ru) | 2019-06-03 |
| US20160318996A1 (en) | 2016-11-03 |
| EP3288974B1 (en) | 2020-11-04 |
| JP6966330B2 (ja) | 2021-11-17 |
| US10745466B2 (en) | 2020-08-18 |
| WO2016179101A3 (en) | 2016-12-15 |
| CA2984628A1 (en) | 2016-11-10 |
| EP3288974A2 (en) | 2018-03-07 |
| IL255329B (en) | 2021-09-30 |
| RU2759949C2 (ru) | 2021-11-19 |
| KR20180020142A (ko) | 2018-02-27 |
| HK1250991A1 (en) | 2019-01-18 |
| AU2016257751B2 (en) | 2021-01-21 |
| AU2016257751A1 (en) | 2017-11-16 |
| EP3288974A4 (en) | 2018-10-24 |
| CA2984628C (en) | 2023-09-05 |
| NZ774893A (en) | 2024-11-29 |
| IL255329A0 (en) | 2017-12-31 |
| US20190345235A1 (en) | 2019-11-14 |
| ES2846881T3 (es) | 2021-07-30 |
| CN107922482A (zh) | 2018-04-17 |
| ZA201707404B (en) | 2021-06-30 |
| NZ736776A (en) | 2024-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017014002A (es) | Moléculas de direccionamiento del sistema de secreción tipo iii . | |
| EA201991157A1 (ru) | Доставка белков на основе бактерий, аттенуированных по вирулентности | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| MX2017013348A (es) | Construcciones de anticuerpos biespecificos contra cdh3 y cd3. | |
| EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
| SG10201803042PA (en) | Anti-tim-3 antibodies | |
| EP4382169A3 (en) | Antibody constructs for dll3 and cd3 | |
| MA44322A (fr) | Compositions comprenant des souches bactériennes | |
| EP3486256A3 (en) | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau | |
| MA42471A (fr) | Compositions comprenant des souches bactériennes | |
| WO2015109124A3 (en) | Immunomodulatory agents | |
| WO2012109624A3 (en) | Monovalent and multivalent multispecific complexes and uses thereof | |
| HK1206756A1 (en) | Modulated lysine variant species compositions and methods for producing and using the same | |
| EA201890315A1 (ru) | Молекулы антител, связывающие cd22 | |
| PH12019500571A1 (en) | Anti-pd-1 antibodies | |
| HK1220326A1 (zh) | 基於网络微生物组成和方法 | |
| PH12014502179A1 (en) | Ang2-binding molecules | |
| MX378292B (es) | Anticuerpos humanos pac1. | |
| EA201890747A1 (ru) | Способы лечения воспалительных заболеваний | |
| WO2016106458A8 (es) | Virus aav/xbp1s-ha, método de tratamiento genético y su uso en la optimización y mejoramiento de las capacidades cognitivas, de memoria y de aprendizaje | |
| PH12017500722A1 (en) | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof | |
| WO2018071504A3 (en) | Methods of treating diseases with il-23a antibody | |
| WO2016014612A3 (en) | Compositions and methods for the diagnosis of rheumatoid arthritis | |
| AU2017234528A8 (en) | Neutralizing monoclonal antibodies to IL-25 and uses thereof | |
| WO2017002049A3 (en) | Conserved chaperone domain for type vi secretion system |